
Cybrexa Therapeutics Announces New Preclinical Data on Tumor-Selective Peptide-Drug Conjugates at ESMO Targeted ...
alphalex™ peptide-drug conjugates (PDCs) demonstrate tumor-selective delivery and potent anticancer activity Preclinical data show robust efficacy as monotherapy and in combination with standard-of-care treatments Findings potentially position alphalex …